The US Food and Drug Administration (FDA) has designated the investigation of Endogena Therapeutics’ EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track development programme. Fast Track is a process designed to enable patients to benefit earlier from important new drugs for serious conditions. EA-2353 takes a novel, small-molecule approach and selectively […]
Menu ≡ ╳ 
